Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects

13Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Aim The primary aim of our study is to identify physicians who have witnessed a complication attributed to sodium-glucose cotransporter (SGLT2) inhibitors. The secondary aim is to determine the type, severity, and setting of the event (inpatient versus outpatient).Background Diabetes is an increasing public health burden with 9.9% of Canadians expected to be diagnosed with it in 2020. A prominent change with respect to treatment options since the publication of the revised Diabetes Canada guidelines in May 2016 concerned the SGLT2 inhibitors. Their favorable clinical profile has increased interest among clinicians, but there is still reason for caution. Because these drugs are new, the balance of benefits versus risks is not well understood.Methods We conducted a cross-sectional survey of all in-practice physicians (excluding pediatricians). Data were collected through an online survey.Findings Our survey identified 154 physicians who have identified one or more adverse drug reactions (ADRs) related to SGLT2 inhibitor use. A total of 173 ADRs were identified. In total, 20.6% of family physician respondents had witnessed one or more ADRs. The most common complication is mycotic infection (82 cases) with 47% identified as a low level of severity and occurring mostly in the outpatient setting. The second most common complication is diabetic ketoacidosis (43 cases) with 67% identified as a high level of severity and occurring mostly in the inpatient setting. Other identified complications include hyperkalemia (6 cases), renal insufficiency (15 cases), and even amputation (2 cases). Our survey is the first to document real-world complications from SGLT2 inhibitors. In the outpatient setting, mycotic infections are most common and most often benign. In the inpatient setting, diabetic ketoacidosis is the most common and is severe. This is an important take-home message for family physicians to tailor their practice and vigilance according to the practice setting.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Patakfalvi, L., Brazeau, A. S., & Dasgupta, K. (2019). Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects. Primary Health Care Research and Development, 20. https://doi.org/10.1017/S1463423618000476

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

57%

Researcher 4

29%

Professor / Associate Prof. 1

7%

Lecturer / Post doc 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

67%

Nursing and Health Professions 2

13%

Biochemistry, Genetics and Molecular Bi... 2

13%

Pharmacology, Toxicology and Pharmaceut... 1

7%

Save time finding and organizing research with Mendeley

Sign up for free